BioXcel Therapeutics Inc
NASDAQ:BTAI
BioXcel Therapeutics Inc
NASDAQ:BTAI
Price:
2.17 USD
3.83%
Market Closed
Updated:
May 14, 2024
BioXcel Therapeutics Inc
Cost of Revenue
|
BioXcel Therapeutics Inc
Cost of Revenue Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
BioXcel Therapeutics Inc
NASDAQ:BTAI
|
Cost of Revenue
-$1.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$9.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-27%
|
See Also
What is BioXcel Therapeutics Inc's Cost of Revenue?
Cost of Revenue
-1.3m
USD
-1.3m
USD
Based on the financial report for Dec 31, 2023, BioXcel Therapeutics Inc's Cost of Revenue amounts to -1.3m USD.
What is BioXcel Therapeutics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-6 200%
-6 200%
Over the last year, the Cost of Revenue growth was -6 200%.
You don't have any saved screeners yet
